2014年法国治疗中HIV-1患者病毒载量>50拷贝/mL的耐药流行率研究
该研究对2014年法国37个专科中心782例抗逆转录病毒治疗失败患者进行HIV-1蛋白酶、逆转录酶和整合酶基因测序,发现56.3%样本对至少一种药物耐药,耐药率低于2009年,且病毒载量51-200拷贝/mL患者中耐药率达48.5%,提示对所有治疗中病毒载量>50拷贝/mL患者应进行耐药检测。
要点
- 治疗失败患者中56.3%对至少一种抗逆转录病毒药物耐药。
- 病毒载量51-200拷贝/mL患者耐药检出率为48.5%。
- 2014年耐药率低于2009年,提示对所有病毒载量>50拷贝/mL者进行耐药检测。
核心结论
- 2014年法国治疗中HIV-1患者耐药率较2009年下降,但病毒载量>50拷贝/mL者中耐药仍常见,建议对所有此类患者进行耐药检测。
研究设计与样本
- 2014年在法国37个专科中心对782例连续抗逆转录病毒治疗失败患者进行血浆HIV-1蛋白酶、逆转录酶和整合酶基因测序,用ANRS v24算法解读,并与2009年类似调查比较。
主要发现
- 566例获得蛋白酶和逆转录酶序列,382例获得整合酶序列。
- 病毒载量51-200、201-500、501-1000和>1000拷贝/mL患者的测序成功率分别为60%、78%、78%和87%。
- 56.3%样本对至少一种抗逆转录病毒药物耐药。
- 对NRTI、NNRTI、PI和整合酶抑制剂耐药的病人分别占3.9%、8.7%、1.5%和3.4%。
- 病毒载量51-200拷贝/mL患者中48.5%样本检出耐药。
关键数值与推荐
- 耐药定义为对至少一种抗逆转录病毒药物耐药,由ANRS v24算法判定。
- 2014年法国艾滋病关怀中心90.0%患者接受抗逆转录病毒治疗,其中12.0%病毒载量>50拷贝/mL。
- 研究提示法国6.7%接受治疗患者可能传播耐药株。
临床怎么用
- 对 all 治疗中病毒载量>50拷贝/mL的患者应考虑进行HIV-1耐药检测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Surveillance of HIV-1 resistance in treated patients with a detectable viral load (VL) is important to monitor, in order to assess the risk of spread of resistant viruses and to determine the proportion of patients who need new antiretroviral drugs with minimal cross-resistance. METHODS: The HIV-1 protease and reverse transcriptase (RT) and integrase genes were sequenced in plasma samples from 782 consecutive patients on failing antiretroviral regimens, seen in 37 specialized centres in 2014. The genotyping results were interpreted using the ANRS v24 algorithm. Prevalence rates were compared with those obtained during a similar survey conducted in 2009. RESULTS: The protease and RT sequences were obtained in 566 patients, and the integrase sequence in 382 patients. Sequencing was successful in 60%, 78%, 78% and 87% of patients with VLs of 51-200, 201-500, 501-1000 and >1000 copies/mL, respectively. Resistance to at least one antiretroviral drug was detected in 56.3% of samples. Respectively, 3.9%, 8.7%, 1.5% and 3.4% of patients harboured viruses that were resistant to any NRTI, NNRTI, PI and integrase inhibitor (INI). Resistance rates were lower in 2014 than in 2009. Resistance was detected in 48.5% of samples from patients with a VL between 51 and 200 copies/mL. CONCLUSION: In France in 2014, 90.0% of patients in AIDS care centres were receiving antiretroviral drugs and 12.0% of them had VLs >50 copies/mL. Therefore, this study suggests that 6.7% of treated patients in France might transmit resistant strains. Resistance testing may be warranted in all treated patients with VL > 50 copies/mL.
引用
- Assoumou L, Charpentier C, Recordon-Pinson P, et al. Prevalence of HIV-1 drug resistance in treated patients with viral load >50 copies/mL: a 2014 French nationwide study. J Antimicrob Chemother. 2017. PMID: 28333232. doi:10.1093/jac/dkx042
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。